1. U.S Food & Drug Administration. U.S Department of Health and Human Services, Therapeutic Biological Products Approvals. [http://www.accessdata.fda.gov/scripts/cder/onctools/druglist.cfm].
2. EMEA Guideline EMEA/CHMP/BWP/49348/2005, Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues.[http://www.emea.europa.eu].
3. J. Pisani, Y. Bonduelle, Opportunities and barriers in the biosimilar market: evolution or revolution for generics companies? [http://www.ableindia.org/biosimilars.pdf].
4. The FDA's assessment of follow-on protein products: a historical perspective
5. IMS-Health. [http://www.imshealth.com/portal/site/imshealth].